J&J back in court over new gener­ic threat from In­tas, just months af­ter fend­ing off Te­va

Three months af­ter suc­cess­ful­ly fend­ing off Te­va’s pro­posed gener­ic to its schiz­o­phre­nia drug In­ve­ga Susten­na, John­son & John­son’s Janssen unit is back in court ar­gu­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER